Cargando…
Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen
Allogeneic haematopoietic stem cell transplantation (HSCT) is the only available curative therapy for patients with thalassaemia major. With the progress in human leucocyte antigen (HLA) antigen typing technology and supportive care, the outcomes of thalassaemia major have greatly improved in recent...
Autores principales: | Sun, Qixin, Wu, Bingyi, Lan, Hekui, Meng, Fanyi, Ma, Xiaoxiao, Chen, Xinxin, Huang, Zhiwei, Yao, Qianqian, Xu, Jianhui, Huang, Yuxian, Wu, Shaojie, Zhu, Zhigang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120500/ https://www.ncbi.nlm.nih.gov/pubmed/29962035 http://dx.doi.org/10.1111/bjh.15438 |
Ejemplares similares
-
Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019) -
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021) -
Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023) -
Identification of the minimum requirements for successful haematopoietic stem cell transplantation
por: Nishi, Katsuyuki, et al.
Publicado: (2021) -
PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)